Biofourmis, a Singapore-based start-up that uses digital therapeutics for the treatment of chronic conditions, announced on Wednesday that it has closed US$35 million in a series B round of financing from investors including Chinese online healthcare platform Jianke.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?